SCHEMBL1811042

SCHEMBL1811042

O=COc1cccc(NC(=O)c2ccccc2Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 2/20 0.60
KCNK9 Q9NPC2 2/20 0.60
MEN1 O00255 8/20 0.60
KMT2A Q03164 8/20 0.60
MAPT P10636 5/20 0.56
ALDH1A1 P00352 5/20 0.56
RAB9A P51151 1/20 0.56
F2R P25116 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SMO Q99835 1/20 0.52
PNLIP P16233 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
ALOX12 P18054 1/20 0.52
RXFP1 Q9HBX9 1/20 0.51
PAX8 Q06710 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1810666 0.84 RAB9A (0.71) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL11590385 0.83 KMT2A (0.83) KCNK3KCNK9MEN1KMT2AMAPT
SCHEMBL11587410 0.82 KMT2A (0.71) KCNK3KCNK9MEN1KMT2AMAPT
SCHEMBL1814910 0.82 ALDH1A1 (0.58) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL1817266 0.80 NPC1 (0.56) KCNK3KCNK9MEN1KMT2AMAPT
SCHEMBL18789745 0.79 KCNK3 (0.65) KCNK3KCNK9MEN1KMT2AMAPT
SCHEMBL1811761 0.78 NPC1 (0.71) KCNK3KCNK9MEN1KMT2AMAPT
SCHEMBL7350331 0.78 MTNR1A (0.55) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL15778718 0.78 FADS1 (0.74) KCNK3KCNK9MEN1KMT2AMAPT
SCHEMBL11590267 0.78 ALDH1A1 (0.74) KCNK3KCNK9MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
EP-2318358-A2 ACYLAMINOBENZAMIDE DERIVATIVES Bayer CropScience AG (DE) 2011-05-11 EP disclosed
WO-2010015355-A2 NOVEL ACYLAMINOBENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 KCNK3 174/4885KCNK9 461/4885MEN1 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.